- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO's New Strategy to Define 'Value' in Cancer Care
The American Society of Clinical Oncology (ASCO) has launched a strategic initiative to define value in cancer care.
The American Society of Clinical Oncology (ASCO) has launched a strategic initiative to define value in cancer care.
The organization is currently developing a working definition of value that is specific to oncology, and their Value in Cancer Care Task Force is working on an algorithm that will help oncologists determine the value of different cancer treatments. Within this framework, value will be defined by clinical benefit, toxicity, and cost.
The recent ASCO State of Cancer Care in America: 2014 report makes it clear that the United States cannot sustain the continually rising cost of cancer care, said Lowell Schnipper, MD, chair of Value in Cancer Care Task Force.
It is projected that the annual cost will increase to $173 billion by 2020, which is an increase of 40% from 2010, he told to Medscape Medical News. At the same time, the demand for cancer care services is growing significantly, in large part because of the aging population, and it is estimated that the number of new cancer cases in United States will increase by 45% by 2030.
Read the full story here: http://bit.ly/1j5Vh9k
Source: Medscape
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
